Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Director departure
ALPHARMA INC (ALO) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/06/2009 8-K Quarterly results
01/05/2009 8-K Form 8-K -- Current report
12/12/2008 8-K Form 8-K -- Current report
10/31/2008 8-K Form 8-K -- Current report
10/29/2008 8-K Quarterly results
Docs: "Alpharma Reports Third Quarter 2008 EPS of $0.10"
09/24/2008 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Alpharma Licenses Durect's Novel Bupivacaine Patch Bridgewater, NJ September 22, 2008"
09/24/2008 8-K Other Events
09/05/2008 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex...
Docs: "Rights Agreement, between Alpharma Inc. and Computershare Trust Company, N.A., as Rights Agent, which includes the Form of Certificate of Designations for the Series B Junior Participating Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights as Exhibit C",
"Bridgewater, NJ...September 2, 2008..."
09/02/2008 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "(c)",
"(d)"
09/02/2008 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Alpharma Announces Acceptance of the EMBEDA™ Capsule NDA Filing"
08/22/2008 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "ALPHARMA RESPONDS TO UNSOLICITED PROPOSAL BY KING PHARMACEUTICALS, INC."
07/30/2008 8-K Quarterly results
Docs: "Alpharma Reports Second Quarter 2008 Revenue Growth of 25% from Continuing Operations Pharmaceutical Revenue Gains Outpace Declines in Animal Health U.S. Livestock Sales"
07/01/2008 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Alpharma Announces the Resubmission of a New Drug Application for EMBEDA™ Capsules"
06/24/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "ALPHARMA ANNOUNCES CHANGES TO EXECUTIVE LEADERSHIP"
05/12/2008 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Alpharma Inc. 2003 Omnibus Incentive Compensation Plan, amended and restated as of February 22, 2008, is filed as an Exhibit to this Report",
"Alpharma Inc. Employee Stock Purchase Plan, amended and restated effective as of March 11, 2008, is filed as an Exhibit to this Report",
"Gain on Sale of API Business Increased by $8.0 Million, to $209.5 Million"
05/05/2008 8-K Quarterly results
Docs: "Alpharma Reports First Quarter 2008 Revenue Growth of 33% from Continuing Operations"
04/21/2008 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Alpharma to Withdraw and Resubmit its New Drug Application for EMBEDA&trade"
04/14/2008 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "ALPHARMA ANNOUNCES UPDATED FINANCIAL OUTLOOK FOR 2008"
04/09/2008 8-K/A Financial Statements and Exhibits
Docs: "Unaudited Pro Forma Financial Statement Information"
04/07/2008 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Docs: "PRESS RELEASE ISSUED ON APRIL 1, 2008",
"Unaudited Pro Forma Financial Statement Information"
03/13/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "Amended Alpharma Inc. Short-Term Incentive Plan, effective January 1, 2008"
02/29/2008 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Alpharma Submits New Drug Application for EMBEDA&trade"
02/26/2008 8-K Quarterly results
Docs: "Alpharma Reports Double-Digit Full Year and Fourth Quarter 2007 Revenue Growth"
02/07/2008 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Stock and Asset Purchase Agreement dated February 6, 2008, among Alfanor 7152 AS (under change of name to Otnorbidco AS), Otdelholdco Inc., Otdenholdco ApS, Alpharma Inc., Alpharma (Luxembourg) S.àr.l., Alpharma Bermuda G.P., and Alpharma International (Luxembourg) S.àr.l",
"Letter Agreement dated February 6, 2008, amending the Amended and Restated Loan and Security Agreement, as amended, among Alpharma Inc., certain of its subsidiaries, various financial institutions party thereto from time to time and Bank of America, N.A., in its capacity as a lender and collateral and administrative agent",
"ALPHARMA ANNOUNCES THE SALE OF ITS ACTIVE PHARMACEUTICAL INGREDIENTS"
01/31/2008 8-K Entry into a Material Definitive Agreement
12/18/2007 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Company Presentation"
12/10/2007 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated By-Laws, effective December 4, 2007, is filed as an Exhibit to this Report",
"Change in Control Plan, as amended and restated, effective January 1, 2008, is filed as an Exhibit to this Report"
10/30/2007 8-K Quarterly results
Docs: "Alpharma Reports Third Quarter 2007 EPS of $0.34 22% Revenue Growth in Pharmaceuticals, Abuse Deterrent Phase III Clinicals on Track Bridgewater, NJ October 29, 2007 Alpharma Inc. , a global specialty pharmaceutical company, announced third quarter 2007 diluted earnings per share of $0.34, versus EPS of $0.31 in the third quarter of 2006. Revenue of $175.8 million in the third quarter of 2007 increased 6.4% versus the third quarter of 2006, driven principally by gains in the company's Pharmaceuticals business. Operating income in the third quarter of 2007 was $19.7 million, a decrease of $2.5 million compared to last year's third quarter, reflecting $6.5 million of increased research and development spending, primarily related to the company's abuse-deterrent pain product platform in its P..."
10/10/2007 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Warrant Agreement, between the Company and IBSA is filed as an Exhibit to this Report"
09/10/2007 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
09/06/2007 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "ALPHARMA LICENSES NOVEL NSAID TOPICAL PAIN DRUG",
"Company Presentation"
08/21/2007 8-K Entry into a Material Definitive Agreement
08/01/2007 8-K Quarterly results
07/10/2007 8-K Entry into a Material Definitive Agreement
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy